Day: March 9, 2026

Today, 9 March 2026, KommuneKredit has published its Annual Report 2025. SummaryProfit before value adjustments and tax came to DKK 507 million, down by DKK 16 million on the year-earlier period, which is in line with our guidance in the interim report. Comprehensive income for the year amounted to DKK -44 million compared with DKK 8 million in 2024. Net interest income came to DKK 641 million for 2025, down by DKK 89 million on last year. The value of total loans and leases was up by DKK 6 billion to DKK 200 billion at end-2025. Common Equity Tier 1 (CET1) capital, which corresponds to equity, declined from 10,188 million at end-2024 to DKK 10,099 million.Since 1899, KommuneKredit has provided funding to municipalities and regions in Denmark through the issuance of bonds in the international capital markets. That funding model was...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical models of pancreatic cancer, lung cancer and ovarian cancer are presentedThe development of kRAS inhibitors for different types of solid tumors is currently an area of intense global activityMelbourne, Australia, March 09, 2026 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that compelling data describing new clinical opportunities for its lead drug narmafotinib was presented at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics in Los Angeles, California on Friday March 6. The poster presentation discloses preclinical data demonstrating...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancers Mechanisms of action support enhanced activity of GSK-3β plus RAS inhibition Preclinical combination results expected in 2H2026CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies. Despite recent advances in RAS-targeted therapies, adaptive...

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Mink Ventures Corporation (TSXV:MINK) (“Mink” or the “Company“) today announced that it has completed a single, vertical drill hole (549 meters) at its Montcalm Ni Cu Co project, Timmins Ontario (Figure 1). Mink’s Montcalm project, located within the Montcalm Gabbro Complex, is adjacent to Glencore’s Montcalm Mine, with historical production of 3.93 million tonnes of ore grading 1.25% Ni, 0.67% Cu and 0.051% Co (Ontario Geological Survey, Atkinson, 2010). The objective of the drill program at Montcalm was to drill test a deep seated, high priority, 3D Borehole Induced Polarization (BHIP) target with coincident airborne VTEM, airborne gravity, and airborne magnetic high responses, located approximately 500 meters below surface (Figure 3). The BHIP target zone shown in Figure...

Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning. CHARLOTTE, N.C., March 09, 2026 (GLOBE NEWSWIRE) — Dentsply Sirona and Siemens Healthineers are pleased to share key findings from the clinical trial for validation of their dental-dedicated MRI system. In addition to confirming its significant potential...

Ceremony highlights Eagle’s recent public listing and Nasdaq debut under ticker “NUCL” RENO, Nev., March 09, 2026 (GLOBE NEWSWIRE) — Eagle Nuclear Energy Corp. (“Eagle” or the “Company”), a next-generation nuclear energy company which owns the largest conventional, measured and indicated uranium deposit in the United States, today announced that CEO Mark Mukhija will ring the Nasdaq Opening Bell at 9:30 a.m. ET on Wednesday, March 11, in recognition of the Company’s recent public listing. Eagle officially commenced trading on the Nasdaq on February 25, 2025, under the ticker symbols “NUCL”, marking a new chapter as a publicly traded U.S.-focused uranium development company. Eagle is the first domestic uranium resource exploration company with exclusive small modular reactor (SMR) technology to list on a U.S. exchange. Anchored...

March 9, 2026 Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life’s a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization’s vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life’s a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated exclusively to FAP, providing essential resources, community support, and awareness for patients and families facing this rare genetic...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today presented encouraging preclinical data evaluating TN-301, the company’s highly selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s...

— The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide — — Interim analysis expected in the first quarter calendar year 2027– — Final topline clinical data expected in the fourth quarter calendar year 2027– MIAMI, FL, March 09, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that it has enrolled the first patient in its Phase 2b PLATEAU clinical trial of enobosarm, an oral selective androgen receptor modulator (SARM), to preserve muscle and physical...

ROCHESTER, NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — Syntec Optics (Nasdaq: OPTX), a leading provider of mission-critical technologies for defense tech and other vibrant end-markets, today announced it has secured over $4 million in defense purchase orders.  As global combat environments evolve, Syntec Optics is playing a pivotal role in providing the high-precision optical products required for next-generation battlefield dominance.  These new orders support the previously announced participation in a diverse range of mission-critical platforms for U.S. Defense, including missile guidance, compact lasers, surveillance, targeting, aiming, night-vision, and mixed-reality (XR/AR) situational awareness. The new orders for a wide range of platforms reinforce Syntec’s position as a key supplier for high-profile defense initiatives. Syntec...